United States News All stories

Innovent Biologics and Lilly (NYSE:LLY) entered a commercialization agreement for Verzenios (abemaciclib) in mainland China, shifting commercial control to Innovent.

Hafnia (NYSE:HAFN) said Chief Executive Officer Mikael Skov will step down on 1 September 2026, with EVP Søren Steenberg Jensen appointed as his successor.

Evotec (NASDAQ:EVO) launched J.TRAIN, a turnkey biologics manufacturing model designed to place its continuous manufacturing technology inside partner-owned facilities.

Cal-Maine Foods (NASDAQ:CALM) said it has reached an agreement to resolve claims brought by the U.S. Department of Justice and 17 state attorneys general following a 15-month investigation into egg pricing practices.

QXO (NYSE:QXO) said its stockholders approved the issuance of shares needed to complete its acquisition of TopBuild (NYSE:BLD), alongside separate approval from TopBuild shareholders for the merger agreement.

Hormel Foods (NYSE:HRL) entered a definitive agreement to sell its Brazilian operations, which operate under the CERATTI brand, to Zanchetta Alimentos LTDA.

Genco Shipping & Trading (NYSE:GNK) said its board has unanimously rejected Diana Shipping’s extended unsolicited $24.80 per-share cash tender offer, saying it undervalues the company.

Air T (NASDAQ:AIRT) reported fiscal 2026 revenue of $327.1 million, compared with $291.5 million a year earlier, reflecting 12% growth that included contributions from its Rex acquisition.

Gilat Satellite Networks (NASDAQ:GILT) said it secured $43 million in new orders for its Sidewinder electronically steered antenna (ESA) terminals from a major in-flight connectivity service provider.

REGENXBIO (NASDAQ:RGNX) said it has dosed the first patient in the Phase IIb/III NAAVIGATE trial evaluating surabgene lomparvovec in diabetic retinopathy using suprachoroidal delivery.

Satellos Bioscience (NASDAQ:MSLE) said the U.S. Food and Drug Administration has granted Fast Track designation to SAT-3247 for the treatment of Duchenne muscular dystrophy.

Palvella Therapeutics (NASDAQ:PVLA) said it has submitted the first module of a rolling New Drug Application to the U.S. Food and Drug Administration for QTORIN 3.9% rapamycin gel.

iHuman (NYSE:IH) reported first-quarter 2026 revenue of RMB182.5 million, compared with RMB210.4 million in the same period last year, showing a year-over-year decline.

Comcast (NASDAQ:CMCSA) said it will divide its operations into two standalone public companies, separating its media assets from its connectivity and technology businesses through a tax-free spin-off.

BrainsWay (NASDAQ:BWAY) reported positive real-world data from what it described as the largest analysis of Deep Transcranial Magnetic Stimulation in patients with comorbid post-traumatic stress disorder and major depressive disorder.

Zentek (NASDAQ:ZTEK) said it has secured a pathway to sell its ZenGUARD enhanced air filtration media in the United States through an exclusive eight-year licensing agreement with Applied Silver.

Roadzen (NASDAQ:RDZN) reported its best quarter and fiscal year with fourth quarter revenue of $16.1 million, up 42% year over year and 12% sequentially.

Tonix Pharmaceuticals (NASDAQ:TNXP) said it enrolled the first patient in HORIZON, a Phase 2, randomized, double-blind, placebo-controlled study of TNX-102 SL 5.6 mg for adults with major depressive disorder.

HP (NYSE:HPQ) announced a strategic partnership with OpenAI to deploy its Frontier enterprise AI platform across HP’s global business operations.

Artivion (NYSE:AORT) announced that the U.S. Food and Drug Administration has granted premarket approval for its AMDS Hybrid Prosthesis for the treatment of acute DeBakey Type I aortic dissections with malperfusion.

Helus Pharma (NASDAQ:HELP) reported fiscal 2026 results with cash of $157.3 million as of March 31, 2026.

Neurogene (NASDAQ:NGNE) reported updated Phase 1/2 clinical data showing 47 total developmental milestone gains across 10 participants treated with NGN-401 gene therapy for Rett syndrome.

Martin Marietta (NYSE:MLM) said it will combine with Lhoist North America in a transaction valued at about $13.5 billion, structured as a mix of cash and stock consideration.

Rocket Lab (NASDAQ:RKLB) agreed to acquire Iridium (NASDAQ:IRDM) in a transaction valuing the combined deal at about $8 billion enterprise value, combining cash, stock, and structured consideration for shareholders.